...10/14 mg strengths. A 90 tablet package has a wholesale acquisition cost (WAC) of $440. Symplmed...
...from Xoma Corp. (NASDAQ:XOMA, Berkeley, Calif.) under a 2013 deal (see BioCentury, July 15, 2013). Symplmed Pharmaceuticals LLC...

...Prestalia perindopril/amlodipine from Symplmed to treat hypertension. Symplmed plans to launch the drug this quarter. Symplmed...
...amlodipine, a dihydropyridine calcium channel blocker. Servier markets the drug as Coveram outside the U.S. Symplmed Pharmaceuticals LLC...

...is indicated for use in patients whose blood pressure is not adequately controlled on monotherapy. Symplmed...

...plans to launch the product “shortly,” but declined to disclose pricing information or financial details. Symplmed...
...from Servier (Neuilly-sur-Seine, France) in 2012 (see BioCentury, Feb. 6, 2012 & July 15, 2013). Symplmed Pharmaceuticals LLC...

...the market have made hypertension a no-fly zone for most biotechs and even some pharmas. Symplmed Pharmaceuticals LLC...
...drugs that is designed to improve patient adherence while reducing costs. The test case for Symplmed's...
...Mentioned Servier , Neuilly-sur-Seine, France Symplmed Pharmaceuticals LLC , Berkeley, Calif. Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Sidebars Symplmed Pharmaceuticals LLC...

...out its Dyrct Axess marketing platform this quarter using Aceon perindopril as its test case. Symplmed...
...ACE inhibitors and calcium channel blockers, while adherence is a problem because patients are asymptomatic. Symplmed...
...said Symplmed hopes to shift patients onto the combination product. In conjunction with the spinout, Symplmed...

...and CMO August Troendle, former Xoma employees, founded Symplmed in May to market the products. Symplmed...
...U.S. in 91 countries. Coveram is a fixed-dose combination of perindopril arginine plus amlodipine besylate. Symplmed...
...from Servier and U.S. commercialization rights to Aceon in 2012 (see BioCentury, Feb. 6, 2012). Symplmed Pharmaceuticals LLC...